Skip to main content

Advertisement

SpringerLink
Log in

Antimuscarinic therapy in men with lower urinary tract symptoms: What is the evidence?

  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Lower urinary tract symptoms (LUTS) in men have, until recently, been assumed to arise from bladder outlet obstruction (BOO) caused by benign prostatic hyperplasia. Given this presumption, all manifestations (obstructive and irritative) of LUTS have been presumed to be responsive to therapy for prostatic disorders such as α-blockade (with or without the relatively recent addition of 5α-reductase inhibitors) or surgical intervention for benign prostatic hyperplasia. However, evidence demonstrates that persistence of irritative urinary symptoms is often encountered in men despite presumed adequate management of their obstructive complaints. Although antimuscarinic drugs have been found to be effective for irritative urinary symptoms attributed to the overactive bladder syndrome, concern regarding the use of this class of drugs in men with even potential coexistent BOO has limited the use of these drugs. Data are now accumulating that suggest that the antimuscarinic class may be used in men with bothersome, irritative symptoms, despite the presence of BOO (as defined by symptoms and urodynamics) and with a reasonable expectation of efficacy and little added risk. Critical evaluation of this evidence suggests that a role may exist for the antimuscarinic class in management of LUTS in men. However, areas of incomplete knowledge, including the risk associated with long-term (greater than 3 months) use of these drugs and the value of the antimuscarinic class as monotherapy in men with LUTS, still remain to be investigated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Girman CJ, Jacobsen SJ, Tsukamoto T, et al.: Health related quality of life associated with lower urinary tract symptoms in four countries. Urology 1998, 51:428–433.

    Article  PubMed  CAS  Google Scholar 

  2. Peters TJ, Donovan JL, Kay HE, et al.: The International Continence Society Benign Prostatic Hyperplasia Study: the bothersomeness of urinary symptoms. J Urol 1997, 157:885.

    Article  PubMed  CAS  Google Scholar 

  3. Knutson T, Edlund C, Fall M, Dahlstrand C: BOO with coexisting overactive bladder dysfunction—an everyday urological dilemma. Neurourol Urodyn 2001, 20:237–247.

    Article  PubMed  CAS  Google Scholar 

  4. Laniado ME, Ockrim JL, Marronaro A, et al.: Serum prostate specific antigen to predict the presence of bladder outlet obstruction in men with urinary symptoms. BJU Int 2004, 94:1283–1286.

    Article  PubMed  Google Scholar 

  5. Eckhardt MD, van Verooij GE, Boon TA: Symptoms, prostate volume, and urodynamic findings in elderly male volunteers without and with LUTS and in patients with LUTS suggestive of benign prostatic hyperplasia. Urology 2001, 58:966–971.

    Article  PubMed  CAS  Google Scholar 

  6. Lee JY, Kim HW, Lee SJ, et al.: Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 2004, 94:817. A sequential therapy trial using combination therapy in men initially stabilized on α-blockers.

    Article  PubMed  CAS  Google Scholar 

  7. Chapple CR: Pharmacologic therapy of benign prostatic hyperplasia/ lower urinary tract symptoms: an overview for the practicing clinician. BJU Int 2004, 94:738.

    Article  PubMed  Google Scholar 

  8. Hyman MJ, Groutz A, Blaivas JG: Detrusor instability in men; correlation of lower urinary tract symptoms with urodynamic findings. J Urol 2001, 166:550.

    Article  PubMed  CAS  Google Scholar 

  9. Knutson T, Schafer W, Fall M, et al.: Can urodynamic assessment of outflow obstruction predict outcome from watchful waiting? — A four year follow-up study. Scand J Urol Nephrol 2001, 35:463.

    Article  PubMed  CAS  Google Scholar 

  10. Abrams P: Tolterodine therapy in men with bladder outlet obstruction and symptomatic detrusor overactivity is not associated with urinary safety concerns [abstract 1048]. J Urol 2002, 167(Suppl):266.

    Google Scholar 

  11. Abrams P, Kaplan S, De Koning Gans HJ, Millard R: Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006, 175:999–1004. This is a very well-documented trial using thorough urodynamic evaluation to completely characterize outlet obstruction in treated men.

    Article  PubMed  CAS  Google Scholar 

  12. Abrams P: Bladder outlet obstruction index, bladder contractility index, and bladder voiding efficiency: three simple indices to define bladder voiding function. BJU Int 1999, 84:14.

    Article  PubMed  CAS  Google Scholar 

  13. Athanasopoulos A, Gyftopoulos K, Giannitsas K, et al.: Combination treatment with an alpha blocker plus an anticholinergic for bladder outlet obstruction: A prospective, randomized, controlled study. J Urol 2003, 169:2253–2256. This is a combination study with patients well-characterized with urodynamics. Also, it is a reasonable assessment of adverse event outcomes.

    Article  PubMed  CAS  Google Scholar 

  14. Lukacs B, Comet D, Grange JC, Thibault P: Construction and validation of a short-form benign prostatic hypertrophy health related quality of life questionnaire. BPH group in general practice. Br J Urol 1997, 80:722.

    PubMed  CAS  Google Scholar 

  15. Saito H, Yamada T, Oshima H, et al.: A comparative study of the efficacy and safety of tamsulosin hydrochloride alone and combination of propiverine hydrochloride and tamsulosin hydrochloride in the benign prostatic hypertrophy with pollakisuria and/or urinary incontinence. Jpn J Urol Surg 1999, 12:525–536.

    Google Scholar 

  16. Lee K-S, Choo M-S, Kim D-Y, et al.: Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointerstinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol 2005, 174:1334–1338. This is a study that uses sequential addition of antimuscarinic medication in men who failed initial therapy with α-blockade but showed substantial improvement in symptoms with combined therapy.

    Article  PubMed  CAS  Google Scholar 

  17. Kaplan SJ, Walmsley K, Te A: Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 2005, 174:2273–2276. The only study to date of antimuscarinic treatment in men who have failed prior therapy for LUTS.

    Article  PubMed  Google Scholar 

  18. Macdiarmid S, Chen A, Tu N, et al.: Effects of tamsulosin and extended release oxybutynin on lower urinary tract symptoms in men [abstract 1639]. J Urol 2006, 175:528. A combination study using initial therapy with both classes of medications rather than sequential addition.

    Article  CAS  Google Scholar 

  19. Roehrborn CG, Guan E, Wang JT, et al.: Efficacy and safety of tolterodine in male patients with overactive bladder and urinary incontinence. Paper presented at the Society of Female Urology and Urodynamic. Orlando, FL; 2005.

  20. Chapple CR, Roehrborn CG: A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 2006, 49:651–659. A review commentary on the evolving understanding of male LUTS, including review of apropos use of nomenclature and role of urodynamic evaluation in patients with mixed symptoms.

    Article  PubMed  Google Scholar 

  21. Novara G, Galfano A, Ficarra V, Artibani W: Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: a systemic review. Eur Urol 2006, In press.

Download references

Author information

Authors and Affiliations

  1. Department of Urologic Surgery, Vanderbilt University Medical Center, Room A1302, Medical Center North, 37232, Nashville, TN, USA

    Roger Dmochowski MD

Authors
  1. Roger Dmochowski MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roger Dmochowski MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dmochowski, R. Antimuscarinic therapy in men with lower urinary tract symptoms: What is the evidence?. Curr Urol Rep 7, 462–467 (2006). https://doi.org/10.1007/s11934-006-0055-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-006-0055-4

Keywords

Search

Navigation